These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 35175662)

  • 1. N,N-dimethyltryptamine and Amazonian ayahuasca plant medicine.
    James E; Keppler J; L Robertshaw T; Sessa B
    Hum Psychopharmacol; 2022 May; 37(3):e2835. PubMed ID: 35175662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ayahuasca: Psychological and Physiologic Effects, Pharmacology and Potential Uses in Addiction and Mental Illness.
    Hamill J; Hallak J; Dursun SM; Baker G
    Curr Neuropharmacol; 2019; 17(2):108-128. PubMed ID: 29366418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypotheses regarding the mechanisms of ayahuasca in the treatment of addictions.
    Liester MB; Prickett JI
    J Psychoactive Drugs; 2012; 44(3):200-8. PubMed ID: 23061319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dimethyltryptamine: Endogenous Role and Therapeutic Potential.
    Rodrigues AV; Almeida FJ; Vieira-Coelho MA
    J Psychoactive Drugs; 2019; 51(4):299-310. PubMed ID: 31018803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurobiological research on N,N-dimethyltryptamine (DMT) and its potentiation by monoamine oxidase (MAO) inhibition: from ayahuasca to synthetic combinations of DMT and MAO inhibitors.
    Egger K; Aicher HD; Cumming P; Scheidegger M
    Cell Mol Life Sci; 2024 Sep; 81(1):395. PubMed ID: 39254764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psychedelic Therapy: A Primer for Primary Care Clinicians-N,N-Dimethyltryptamine and Ayahuasca.
    Shinozuka K; Tabaac BJ; Arenas A; Beutler BD; Cherian K; Evans VD; Fasano C; Muir OS
    Am J Ther; 2024 Mar-Apr 01; 31(2):e112-e120. PubMed ID: 38518268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pharmacological interaction of compounds in ayahuasca: a systematic review.
    Ruffell S; Netzband N; Bird C; Young AH; Juruena MF
    Braz J Psychiatry; 2020; 42(6):646-656. PubMed ID: 32638916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Altered State of Consciousness and Mental Imagery as a Function of N, N-dimethyltryptamine Concentration in Ritualistic Ayahuasca Users.
    Ramaekers JG; Mallaroni P; Kloft L; Reckweg JT; Toennes SW; van Oorsouw K; Mason NL
    J Cogn Neurosci; 2023 Sep; 35(9):1382-1393. PubMed ID: 37159257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical investigations of the therapeutic potential of ayahuasca: rationale and regulatory challenges.
    McKenna DJ
    Pharmacol Ther; 2004 May; 102(2):111-29. PubMed ID: 15163593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autonomic, neuroendocrine, and immunological effects of ayahuasca: a comparative study with d-amphetamine.
    Dos Santos RG; Valle M; Bouso JC; Nomdedéu JF; Rodríguez-Espinosa J; McIlhenny EH; Barker SA; Barbanoj MJ; Riba J
    J Clin Psychopharmacol; 2011 Dec; 31(6):717-26. PubMed ID: 22005052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ayahuasca - potential therapeutic properties in psychiatry. Research review.
    Barabasz-Gembczyk A; Kucia K
    Psychiatr Pol; 2020 Apr; 54(2):381-389. PubMed ID: 32772067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dark Classics in Chemical Neuroscience: N, N-Dimethyltryptamine (DMT).
    Cameron LP; Olson DE
    ACS Chem Neurosci; 2018 Oct; 9(10):2344-2357. PubMed ID: 30036036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacology of ayahuasca administered in two repeated doses.
    Dos Santos RG; Grasa E; Valle M; Ballester MR; Bouso JC; Nomdedéu JF; Homs R; Barbanoj MJ; Riba J
    Psychopharmacology (Berl); 2012 Feb; 219(4):1039-53. PubMed ID: 21842159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ayahuasca for the Treatment of Depression.
    Palhano-Fontes F; Soares BL; Galvão-Coelho NL; Arcoverde E; Araujo DB
    Curr Top Behav Neurosci; 2022; 56():113-124. PubMed ID: 34761362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemical Composition of Traditional and Analog Ayahuasca.
    Kaasik H; Souza RCZ; Zandonadi FS; Tófoli LF; Sussulini A
    J Psychoactive Drugs; 2021; 53(1):65-75. PubMed ID: 32896230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ayahuasca and the traveller: A scoping review of risks and possible benefits.
    Houle SKD; Evans D; Carter CA; Schlagenhauf P
    Travel Med Infect Dis; 2021; 44():102206. PubMed ID: 34785376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toxicokinetics and Toxicodynamics of Ayahuasca Alkaloids
    Brito-da-Costa AM; Dias-da-Silva D; Gomes NGM; Dinis-Oliveira RJ; Madureira-Carvalho Á
    Pharmaceuticals (Basel); 2020 Oct; 13(11):. PubMed ID: 33114119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Daytime Ayahuasca administration modulates REM and slow-wave sleep in healthy volunteers.
    Barbanoj MJ; Riba J; Clos S; Giménez S; Grasa E; Romero S
    Psychopharmacology (Berl); 2008 Feb; 196(2):315-26. PubMed ID: 18030450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Pathways of the Therapeutic Effects of Ayahuasca, a Botanical Psychedelic and Potential Rapid-Acting Antidepressant.
    Rossi GN; Guerra LTL; Baker GB; Dursun SM; Saiz JCB; Hallak JEC; Dos Santos RG
    Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of alpha oscillations through serotonin-2A receptor activation underlies the visual effects of ayahuasca in humans.
    Valle M; Maqueda AE; Rabella M; Rodríguez-Pujadas A; Antonijoan RM; Romero S; Alonso JF; Mañanas MÀ; Barker S; Friedlander P; Feilding A; Riba J
    Eur Neuropsychopharmacol; 2016 Jul; 26(7):1161-75. PubMed ID: 27039035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.